Introduction
Calmodulin (CaM)' is a ubiquitous 17,000 Mr intracellular Ca2"-binding protein known to activate many Ca2"-dependent enzymes and thereby plays a fundamental role in regulation of many physiological events (see monograph, 1, and reviews 2-5). All tissues contain large amounts of CaM ( 10-6 M) (6) , and the list of known CaM-regulated processes is no doubt far from complete. Trifluoperazine and other phenothiazines inactivate CaM (7) by binding to specific sites on CaM in a Ca2"-dependent manner (8) . It has been argued that these represent nonspecific hydrophobic interactions rather than true pharmacologic antagonism (9, 10) . However, several neuroleptic drugs and other classes of drugs have been shown to bind directly to CaM and specifically antagonize its effects (11, 12) , and relationships between drug structure and inhibition have been established (13, 14) . No clinically employed drug is presently known to exert its principal pharmacologically desired effects by binding to CaM, although this is an active area of investigation (15) .
Clinical medicine is presently experiencing an explosion of interest in use of Ca2" antagonists for the treatment of cardiovascular diseases (see monograph 16 , and review 17). Two classes of Ca2" channel blocking drugs are currently used in clinical practice in the United States: "use-dependent" agents (verapamil and diltiazem) and direct channel "plugs" (nifedipine). Two vascular smooth muscle relaxants, bepridil and cetiedil, are currently used in Europe to treat angina and claudication, and these drugs produce some effects similar to the recognized Ca2"-channel blockers and bepridil and cetiedil include: (a) much higher concentrations of bepridil and cetiedil are required, (b) the electrophysiologic effects are distinct, and (c) bepridil and cetiedil both produce effects on a wide range of other tissues. Despite investigation of bepridil and cetiedil in several laboratories, the biochemical mechanisms of their actions are unknown. This report describes the use of a recently developed erythrocyte system for identification and evaluation of potential CaM-inhibitors (18, 19) . It was found that bepridil and cetiedil competitively inhibit Ca2+-dependent CaM binding to membrane receptor sites and displace trifluoperazine from sites on CaM, probably by directly interacting with CaM. The principally desired pharmacologic effect, relaxation of vascular smooth muscle, and possibly effects upon other tissues are probably sequelae of inhibition of CaM-dependent enzymes.
Methods
Reagents. Bepridil, #-42-methylpropoxy)methyl-N-phenyl-N4phenyl- Membrane -preparations. Blood was obtained from normal adult volunteers by venipuncture, anticoagulated with acid citrate dextrose, and stored for up to 3 d at 0°C. Erythrocyte ghost membranes were prepared from erythrocytes washed three times in 0.15 M NaCl, 5 mM NaPO4, pH 7.4, and lysed in 40 vol of ice-cold 7.5 mM NaPO4, 1 mM NaEGTA, 35 Ag/ml phenylmethylsulfonyl fluoride, pH 7.3, centrifuged at 44,000 g for 10 min and washed repetitively until white. The membranes were then washed once in 10 mM Hepes, pH 7.3, and stored at 0°C in 10 mM Hepes, pH 7.3, 0.1 mM dithiothreitol, I mM NaN3 for up to I d. Spectrin-actin stripped membrane vesicles were prepared by incubating fresh ghost membranes in 40 vol of 0.3 mM NaPO4, pH 7.4, at 37°C for 30 min. The vesicles were pelleted at 44,000 g for 25 min, washed again in 10 mM Hepes, pH 7.3, and resuspended to 1.5 mg protein/ml in 10 mM Hepes, 0.1 mM dithiothreitol, I mM NaN3. a-chymotrypsin-digested vesicles were prepared basically as described (19). Spectrin-actin stripped membrane vesicles (1.5 mg protein/ml) were incubated for 45 min at 0°C with 8 Ag/ml a-chymotrypsin (diluted from a fresh stock solution of 4 mg achymotrypsin in I ml of 2 mM HCI), then washed twice in ice cold 10 mM Hepes (pH 7.3) also containing 50 tg/ml phenylmethylsulfonyl fluoride, and resuspended to 1.2 mg protein/ml in 10 mM Hepes, 0.1 mM dithiothreitol, I mM NaN3.
Binding assay. Inhibition of Ca2"-dependent ' minations at these drug and CaM concentrations were not possible due to nonlinearity of these Dixon plots also (not shown). Double reciprocal plots of these data are shown as inserts in Fig. 3 . Enzyme inhibition by all three drugs appears to be competitive with CaM, and the y intercepts approximate the reciprocal of the expected CaM-stimulated Ca2+-ATPase activities, V. = 6-10 nmol Pd/mg membrane protein per minute (19). As was found in the binding studies (Fig. 2) , MM bepridil, and 100 AM cetiedil are at or above the concentrations which produced nearly complete inhibition of CaM binding (Fig. 2) and CaM-activated Ca2+-ATPase (Fig. 3) . These drug concentrations were employed in Ca2+-ATPase assays with concentrations of CaM rising from 2 to 128 nM (Fig. 4) resembles CaM stimulation of the intact enzyme (25). Vesicles with proteolytically stimulated Ca2+-ATPase activity were incubated with increasing concentrations of trifluoperazine, bepridil, and cetiedil (Fig. 5) concentrations of unlabeled trifluoperazine, bepridil, and cetiedil (Fig. 7) . All equilibrium by gently shak-UNLABELED DRUG, FM ing for 15 h at room temperature in the dark in glass beakers containing 20 ml of 0.1 M Hepes, 2.50 mM CaCI2/2.50 mM NaEGTA (pCa = 5.0), 1 mM NaN3, 10 AM [3H~trifluoperazine (80,000 cpm/ml), and also containing increasing concentrations of unlabeled trifluoperazine (A), bepridil (i), or cetiedil (-). The bags were snipped and aliquots from the bags containing CaM in gelatin, the bags containing gelatin alone, and dialysis buffer were assayed for 3H in 5 ml of Beckman Ready-Solv. 100% refers to counts per minute specifically bound to CaM (counts per minute in CaM-gelatin bag minus counts per minute in gelatin bag = 22,500 cpm/200 Ml) after dialysis to equilibrium against 10 MM [3H]trifluoperazine with no additional unlabeled drug present, as described by Weiss (22) .
competitive with respect to CaM. None of the three drugs produced identifiable direct effects upon the membranes: none produced inhibition either of basal Ca2+-ATPase or CaMindependent (proteolytically stimulated) Ca2+-ATPase activity, and none produced reductions in membrane-CaM binding which persisted after membrane washing. Bepridil and cetiedil displaced [3H]trifluoperazine from sites on CaM, although with somewhat less potency than did unlabeled trifluoperazine. Thus, bepridil and cetiedil possess specific CaM-inhibitory properties which resemble those of trifluoperazine in several ways: (a) CaM-membrane interactions are competitively inhibited by these agents, (b) no effects of drugs acting directly on membranes were identified at these concentrations, and (c) the agents displaced trifluoperazine from sites on CaM. While none of the experiments conclusively demonstrated inhibition by direct interaction of bepridil or cetiedil with CaM, when taken together, these data are most consistent with that explanation. However, it is not possible to rule out secondary, reversible interactions of the drug with membrane target sites that result in inhibition of CaM binding. Such studies will require purification of CaM-binding proteins and direct measurements of radiolabeled drugs to these CaM-binding proteins.
Despite Ca2l-dependent target cell lysis by Entamoeba histolytica (40) .
Cetiedil inhibits Ca2+-induced cation fluxes in erythrocytes (41) and may be of value in sickle cell disease (42) (43) (44) (52) . Thus, it is likely that certain effects of bepridil and cetiedil are not due to inhibition of CaM.
Bepridil and cetiedil may belong to a new class of vascular smooth muscle relaxants which achieve their principal pharmacologic effects by inhibition of CaM and other intracellular Ca2+-sensitive processes rather than by direct interaction with the Ca2+ channels which regulate Ca2+ entry. Therefore, bepridil and cetiedil are different from the recognized Ca2" channel blockers (although some of the latter have also been found to interact with CaM) (53) (54) (55) . Certain other smooth muscle relaxants with related structures including naphthalenesulfonamides (W7 and No. 233) and prenylamine (another European coronary vasodilator) interact directly with CaM with comparable affinities, inhibit CaM-activated myosin light chain kinase (12) , and may also be considered members of this class of drugs. These agents all appear to achieve at least some of their principal pharmacologic effects by inhibition of CaM-dependent enzymes. These agents are also distinct from phenothiazines, which produce their principal antipsychotic effects at very low concentrations by interaction with dopamine receptors but produce side effects at higher concentrations probably due to interaction with CaM.
All tissues contain CaM, and since many CaM-dependent enzymes are essential for cell survival, it appears paradoxical that unselective inhibition of CaM is not deleterious. CaM inhibitors have been demonstrated to inhibit progression in the cell cycle from GI to DNA-S phase (56) . Erythrocyte Ca2+-ATPase is inhibited by phenothiazines (57) , and accumulation of intracellular Ca2" can produce toxic activation of intracellular proteases (58) and transglutaminase (59) . Therefore, for CaM inhibition to be clinically useful, there must be inhibition of certain enzymes more than others. Selective inhibition may result from differences in drug levels in different tissues or even by enzyme localizations within a cell. It is also likely that the affinity with which CaM activates certain enzymes may be important in selective enzyme inhibition. The system described in this report may be useful for identification and evaluation of selective CaM inhibitors.
